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ABSTRACT
Background
While vascular endothelial growth factor (VEGF) expression in breast tumors has been
correlated with a poor outcome in the pathogenesis of breast cancer, the expression,
localization, and function of VEGF receptors VEGFR1 (also known as FLT1) and VEGFR2 (also
known as KDR or FLK1), as well as neuropilin 1 (NRP1), in breast cancer are controversial.
Methods and Findings
We investigated the expression and function of VEGF and VEGF receptors in breast cancer
cells. We observed that VEGFR1 expression was abundant, VEGFR2 expression was low, and
NRP1 expression was variable. MDA-MB-231 and MCF-7 breast cancer cells, transfected with
antisense VEGF cDNA or with siVEGF (VEGF-targeted small interfering RNA), showed a
significant reduction in VEGF expression and increased apoptosis as compared to the control
cells. Additionally, specifically targeted knockdown of VEGFR1 expression by siRNA (siVEGFR1)
significantly decreased the survival of breast cancer cells through down-regulation of protein
kinase B (AKT) phosphorylation, while targeted knockdown of VEGFR2 or NRP1 expression had
no effect on the survival of these cancer cells. Since a VEGFR1-specific ligand, placenta growth
factor (PGF), did not, as expected, inhibit the breast cancer cell apoptosis induced by siVEGF,
and since VEGFR1 antibody also had no effects on the survival of these cells, we examined
VEGFR1 localization. VEGFR1 was predominantly expressed internally in MDA-MB-231 and MCF-
7 breast cancer cells. Specifically, VEGFR1 was found to be colocalized with lamin A/C and was
expressed mainly in the nuclear envelope in breast cancer cell lines and primary breast cancer
tumors. Breast cancer cells treated with siVEGFR1 showed significantly decreased VEGFR1
expression levels and a lack of VEGFR1 expression in the nuclear envelope.
Conclusions
This study provides, to our knowledge for the first time, evidence of a unique survival system
in breast cancer cells by which VEGF can act as an internal autocrine (intracrine) survival factor
through its binding to VEGFR1. These results may lead to an improved strategy for tumor
therapy based on the inhibition of angiogenesis.
The Editors’ Summary of this article follows the references.
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The classical role of VEGF in tumor progression is as a
positive regulator of angiogenesis, the process of forming new
capillaries from preexisting blood vessels [1]. Tumor growth
is highly dependent on the ability of tumors to induce their
own vascularization [2]. VEGF expression has been reported
in a number of cancer cell lines and in several clinical
specimens derived from breast, brain, and ovarian cancers [3–
6]. Thus, antagonism of VEGF can effectively prevent tumor
growth through incomplete blood vessel formation [7].
VEGF exerts its effects on endothelial cells in a paracrine
mode after its release by other cells such as tumor cells, or in
an autocrine manner in VEGF-producing endothelial cells.
VEGF binds to its cognate receptors VEGFR1 (also known as
FLT1), VEGFR2 (also known as KDR or FLK1), and neuropilin
1 (NRP1) [8]. VEGFR2 is responsible for initiating signal
transduction pathways within endothelial cells. Following the
binding of VEGF to VEGFR2, VEGF mediates its effects on
proliferation, survival, adhesion, migration, capillary mor-
phogenesis, and gene expression in endothelial cells [8].
VEGFR1 has a relatively minor role in VEGF-mediated signal
transduction as compared to VEGFR2, since its kinase activity
is 10-fold less than that of VEGFR2 [9]. Nonetheless, it has
been shown that VEGFR1 induces growth factors from liver
sinusoidal endothelial cells [10] and mediates the survival of
endothelial cells through VEGF stimulation of the phospha-
tidylinositol 3-kinase/protein kinase B (AKT) pathway [2].
Breast cancer cell lines express both VEGF and the VEGF
receptors VEGFR1, VEGFR2, and NRP1 [11]. The expression
of these receptors in primary breast tumors is controversial.
Some reports have documented the expression of VEGFR1
and VEGFR2 in breast tumors and others have reported very
low to negative expression of both receptors. Furthermore, in
one study the presence of VEGFR1 in breast cancer cells was
shown to be signiﬁcantly correlated with high metastasis risk
and relapse and was considered a marker for breast tumor
aggressiveness [12], while other studies did not detect the
expression of VEGFR1 in breast tumors [13]. Thus, there are
conﬂicting reports regarding the expression and role of
VEGFR1 in breast cancer. Of note, no correlation of survival
or metastasis risk and relapse was found in breast cancer cells
that expressed VEGFR2 [12].
Recent studies have shown that VEGF acts as an autocrine
growth and survival factor for VEGF receptor-expressing
tumor cells [14–16]. However, the mechanism by which VEGF
mediates the survival of tumor cells needs to be investigated
in depth. Here, to address this issue, we analyzed the
expression and function of VEGF and VEGF receptors in
breast cancer cells.
Methods
Reagents
Human recombinant VEGF165 and anti-human VEGF
monoclonal antibody were obtained from Genentech (http://
www.gene.com). For all experiments, we used the VEGF165
isoform when VEGF is indicated. Anti-human VEGFR1
antibody recognizing the intracellular domain of VEGFR1
was obtained from Abcam (http://www.abcam.com; #Ab2350).
Anti-human VEGFR1 antibody raised against the extracel-
lular domain of VEGFR1 was obtained from R&D Systems
(http://www.rndsystems.com; #MAB321), and from Santa Cruz
Biotechnology (http://www.scbt.com). Anti-human VEGFR2
polyclonal antibody and PGF were purchased from R&D
Systems. Anti-human NRP1 and anti-C-terminal Src kinase
(Csk) antibodies were from Santa Cruz Biotechnology.
VEGFR1 blocking antibody was a kind gift of Dr. Masabumi
Shibuya (National University of Tokyo, Institute of Medical
Science, Japan). This monoclonal antibody was shown to act
as a functional blocking antibody against the VEGFR1
receptor [17].
Cell Culture
The MDA-MB-231 and MCF-7 breast cancer cell lines were
obtained from ATCC (http://www.atcc.org) and maintained in
culture medium (DMEM or RPMI containing 10% FBS, 2 mM
L-glutamine). Human brain microvascular endothelial cells
(HBMECs) were purchased from Cell Systems (http://www.
cell-systems.com) and maintained according to the methods
described previously [18,19]. Human umbilical vein endothe-
lial cells (HUVECs) were purchased from Cambrex Bio-
Science (http://www.cambrex.com) and cultured with EGM-2
medium.
Immunoprecipitation and Western Blot Analyses
Cells were lysed in kinase lysis buffer (New England Biolabs,
http://www.neb.com) and lysates were incubated with primary
antibodies at 4 8C. After overnight incubation, Protein G-
Sepharose was added to the reaction mixture and incubated
for 6 h. The immune complexes were precipitated with the
Sepharose beads, washed, and resuspended in SDS-PAGE
sample buffer with reducing agent. The samples were
separated by 7.5% SDS-PAGE and transferred onto nitro-
cellulose membrane (Millipore, http://www.millipore.com).
The membranes were blocked with 5% nonfat dried milk in
PBS and subsequently incubated with primary antibodies
overnight at 4 8C. Bound antibodies were detected by
horseradish peroxidase-conjugated secondary antibodies
and enhanced chemiluminescence (Amersham Pharmacia
Biotech, http://www.amershambiosciences.com).
Generation of MDA-MB-231 Cells Stably Transfected with
Antisense VEGF
Human cDNA clones encoding VEGF were ampliﬁed by
reverse transcription (RT) PCR using the following primers
59-ACGACAGAAGGGGAGCAGAAAG-39 (forward) and 59-
GGAACGTTGCGCTCAGACACA-39 (reverse). These sequen-
ces were analyzed by the BLAST program (National Center
for Biotechnology Information, http://www.ncbi.nlm.nih.gov/
BLAST/) to conﬁrm the speciﬁcity of these sequences and
their absence from other genes. Subsequently, the 576 bp
VEGF cDNA was cloned using the pBluescript II SK (þ/ )
vector (Stratagene, http://www.stratagene.com) and se-
quenced using the T7 promoter and primers. Both sense
and antisense orientations were cloned into the Kpn1
restriction site of the constitutive mammalian expression
vector, pZeoSV (Invitrogen, http://www.invitrogen.com), and
sequenced using the T3 and SP6 primers. MDA-MB-231 cells
were transfected with antisense VEGF vector and selected in
the presence of Zeocin (phleomycin D1; 1 mg/ml). VEGF
expression in the MDA-MB-231 transfectants was analyzed by
Western blotting using polyclonal anti-VEGF antibodies
(Santa Cruz Biotechnology).
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UTP Nick End Labeling Assay
Cells were grown on chamber slides and stained with the
ﬂuorescein in situ cell death detection kit (Boehringer
Mannheim, http://www.roche-applied-science.com), which is
based on the terminal deoxynucleotidyltransferase-mediated
deoxy-UTP nick end labeling (TUNEL) method, according to
the protocol of the manufacturer. After they were washed
with PBS, the cells were mounted and then intracellular
ﬂuorescein-labeled fragmented DNA was detected by micro-
scopic analysis.
RT-PCR
Total cellular RNA was isolated with TRIZol reagent
(Invitrogen). The primers for VEGF, VEGFR1, and VEGFR2
were purchased from R&D Systems, and the RT-PCR was
performed as described in the manufacturer’s protocol (BD
Biosciences Clontech, http://www.bdbiosciences.com/
clontech.shtml). PCR ampliﬁcation was performed using 30
cycles for VEGF and 40 cycles for VEGFR1 and VEGFR2.
Small Interfering RNA
The small interfering RNA (siRNA) oligonucleotides used
in this study were purchased from Dharmacon (http://www.
dharmacon.com). A thorough analysis by BLAST was per-
formed on all siRNA sequences used in this study to
demonstrate that these sequences have no homology to other
genes. Transfection procedures were performed with Oligo-
fectamine Reagent (Invitrogen) in MDA-MB-231 cells or with
DharmaFECT-1 reagent (Dharmacon) in MCF-7 cells accord-
ing to the manufacturers’ protocols. Cells were grown
subconﬂuently on six-well plates and transfected with 200
nM of siRNA. After 5 d of culture, cells were washed and
analyzed further as speciﬁcally indicated.
Retroviral Infection
The siRNA-expressing pSIREN-RetroQ retroviral vector
was used per the manufacturer’s protocol (BD Biosciences
Clontech). The wild-type and mutant VEGFR2 siRNA target-
ing sequences are described in the Results section. For
retroviral production, 293 Phoenix retrovirus packaging cells
were cotransfected with Gag-Pol, pVSVG, and pSIREN-
RetroQ retroviral vectors by using FuGENE 6 reagent
(www.roche-applied-science.com). After 2 d of transfection,
the supernatants were harvested, centrifuged, and passed
through disposable ﬁlters of pore size 0.4 lm. The viral
supernatants were then added to the MDA-MB-231 cells at a
ratio of 1:1 (volume/volume) in the presence of polybrene (8
lg/ml). After 3 d of infection, cells were treated with
puromycin (5 lg/ml) for selection of the stable cells
expressing siRNA.
Cell Cycle Analysis
Cells were harvested, centrifuged and ﬁxed with 70% cold
ethanol for a minimum of 2 h. Ethanol-ﬁxed cells were
centrifuged and washed once with PBS. The cell pellet was
suspended in 0.5 ml of propidium iodide (PI) staining
solution (0.1% Triton X-100, 20 lg/ml of PI, and 0.2 mg/ml
of RNase in PBS) and incubated for 15 min at 37 8C. Samples
were analyzed by ﬂow cytometry, and apoptosis was measured
as the percentage of cells with a sub-G0/G1 DNA content in
the PI intensity–area histogram plot.
Flow Cytometry Analysis
Cells were detached by incubation with 50 mM EDTA in
PBS, centrifuged, and resuspended in PBS containing 1%
BSA. Alternatively, the detached cells were permeabilized
with 90% cold methanol for 10 min and resuspended in PBS
containing 1% BSA. The cells were incubated with VEGFR1-
speciﬁc antibodies (R&D Systems; #MAB321) or control
antibodies for 30 min at 4 8C. After washing with PBS
containing 1% BSA, the cells were incubated with FITC-
conjugated secondary antibodies for 30 min at 4 8C. After a
second washing with PBS, the cells were analyzed by ﬂow
cytometry.
Immunocytochemistry
Confocal immunoﬂuorescence staining was performed on
methanol-ﬁxed MCF-7 and MDA-MB-231 cells. We used two
types of VEGFR1 antibodies: (a) antibodies against the
VEGFR1 extracellular domain (R&D Systems or Santa Cruz
Biotechnology) that interact with both the transmembrane
form of VEGFR1 (the 200 kDa protein) and the soluble form
of VEGFR1 (the 100 kDa protein); and (b) antibodies against
the intracellular domain of VEGFR1 (Abcam; #ab2350), which
recognize only the transmembrane full-length form of
VEGFR1 and not soluble VEGFR1. The cells were permeabi-
lized with PBST (0.1% and 0.5% Triton X-100 in PBS) and
blocked with 3% normal goat or donkey serum in 0.1% PBST,
then incubated in 3% normal goat serum in 0.1% PBST with
primary antibodies against lamin A/C (LMNA) (rabbit poly-
clonal antibody, 1:100, Santa Cruz Biotechnology; H-110),
LMNA (mouse monoclonal antibody, 1:50, Santa Cruz
Biotechnology; #sc-7292), VEGFR1 (goat polyclonal antibody,
1:50, R&D Systems; #MAB321), and VEGFR1 (rabbit poly-
clonal antibody, 1:50, Abcam; #ab2350) overnight at 4 8C.
Cells were then treated with FITC and Texas Red-conjugated
secondary antibody (1:250, Jackson ImmunoResearch) diluted
in 3% normal goat or donkey serum in 0.1% PBST for 1 h at
room temperature. Cells were visualized with the 1003 oil-
immersion objective of a Zeiss 510 laser scanning microscope.
Immunohistochemistry
To examine the expression of VEGFR1 and its localization
at the nuclear membrane in tumor and breast tissues,
immunohistochemical staining was carried out using anti-
VEGFR1 (R&D Systems; #MAB321) and anti-lamin antibodies.
Lamins are known to be the main components of inter-
mediate ﬁlaments in the nuclear membrane. Tissue sections
of human normal breast and invasive ductal breast carcinoma
of varying pathological stages were immunostained for
VEGFR1. Both the primary breast tumors and normal breast
tissues were obtained from CHTN Eastern Division (Univer-
sity of Pennsylvania, Pennsylvania, United States), and were
approved as part of a protocol of the Institutional Review
Board at Beth Israel Deaconess Medical Center. The staining
was performed on 5 lm sections, placed on polylysine-coated
slides. After deparafﬁnization in xylene and rehydration
through graded alcohol, each section was treated with 0.03%
hydrogen peroxide for 5 min and blocked with 3% normal
goat or donkey serum in 0.1% PBST, then incubated in 3%
normal goat serum in 0.1% PBST overnight with primary
antibodies against LMNA (rabbit polyclonal antibody, 1:100,
Santa Cruz Biotechnology; #H-110), LMNA (mouse mono-
clonal antibody, 1:50, Santa Cruz Biotechnology; #sc-7292),
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#MAB321), and VEGFR1 (rabbit polyclonal antibody, 1:50,
Abcam; #ab2350) at 4 8C in a closed chamber. Following
washing, cells were treated with the FITC and Texas Red-
conjugated secondary antibody (1:250, Jackson ImmunoRe-
search) diluted in 3% normal goat serum in 0.1% PBST for 1
h at room temperature. Cells were visualized with the 1003
oil-immersion objective of a Zeiss 510 laser scanning micro-
scope.
Nuclear Extraction
Nuclear and cytoplasmic fractionations were performed
per the manufacturer’s instructions (Pierce Biotechnology,
http://www.piercenet.com). Brieﬂy, 1,000 ll of CER I buffer
was added to 100 llo f53 10
6 cells. After 10 min of
incubation on ice, 55 ll of CER II buffer was added. Following
incubation on ice for 1 min, cell suspension was centrifuged
for 5 min at maximum speed (;16,000 g). The supernatants
were transferred to a prechilled tube and kept on ice or at
 80 8C until use. The pellet was then resuspended with 500 ll
of NER buffer and incubated on ice for 40 min. Following
centrifugation at the maximum speed for 10 min, super-
natants were transferred to prechilled tubes and stored on ice
or at  80 8C until use. To analyze the expression of VEGFR1
in the nuclear and cytoplasmic fractions, 100 lg of these
extracts were loaded onto 4%–12% gradient SDS-PAGE gels,
and transferred to nitrocellulose membranes. The blots were
incubated with anti-VEGFR1 (R&D Systems; #MAB321), anti-
lamin B1 (a nuclear marker), anti-GAPDH (a cytoplasmic
marker), or anti-actin antibodies.
Tumor Formation in Nude Mice
Athymic nude mice were used to assess the effect of
siVEGFR1 on tumor growth in vivo. MDA-MB-231 cells were
transfected with control siRNA (siCTL) or siVEGFR1 for 2 d.
Aliquots of these cells (5 3 10
6) were then analyzed for the
knockdown of VEGFR1 expression by Western blotting. Mice
(ﬁve per group) were subcutaneously inoculated in the ﬂank
area with either 5310
6 of siVEGFR1- or siCTL-MDA-MB-231
cells or with untransfected MDA-MB-231 cells. Tumor
formation in these mice was monitored daily. The experi-
ments were terminated at day 15, since some of the tumors in
the control group reached a size of more than 1.5–2 cm
3 (and
therefore, based on the guidelines of our animal facility, we
had to terminate the experiments). Tumor sizes were
measured and expressed in cm
3.
Statistical Analyses
Data are presented as the mean 6 standard deviation (SD).
The Student t-test and one-way ANOVA were used to assess
the signiﬁcance of independent experiments. The criterion p
, 0.05 was used to determine statistical signiﬁcance.
Results
VEGF Receptor Expression in Human Breast Cancer Cells
Using immunoprecipitation and Western blot analyses, we
examined expression of the VEGF receptors VEGFR1,
VEGFR2, and NRP1 in several breast cancer cell lines.
HBMECs were used as positive cells for VEGF receptor
expression. The breast cancer cell lines include MDA-MB-231,
MDA-MB-453, and BT-474, which are highly aggressive and
form tumors and metastasis in vivo when inoculated into
nude mice. The MCF-7 and T-47D breast cancer cell lines
form tumors when inoculated into nude mice, but are less
tumorigenic as they do not metastasize in vivo in the mice.
We used 5 mg of total breast cancer cell lysates to examine
the expression levels of VEGFR1, VEGFR2, and NRP1.
VEGFR1 expression was abundant in all breast cancer cell
lines, NRP1 expression was variable and observed primarily
in MDA-MB-231 and MCF-7 cells, while the levels of VEGFR2
expression were low (Figure 1A). We next examined the
expression of VEGFR2 in MDA-MB-231 cells by immunocy-
tochemistry staining using anti-VEGFR2 antibody. For the
positive control, MDA-MB-231 cells were transduced with
adenovirus encoding soluble human VEGFR2. As shown in
Figure 1B, unlike the MDA-MB-231 cells transduced with
VEGFR2, no endogenous VEGFR2 expression was detected in
untransfected MDA-MB-231 cells by immunocytochemistry
analysis and confocal microscopy. These data suggest that
VEGFR2 was expressed at relatively low levels compared to
VEGFR1 and NRP1 in breast cancer cells. These results are
consistent with our previous report detailing VEGFR2 mRNA
expression in breast cancer cell lines [19].
As noted above, we found that both MDA-MB-231 and
MCF-7 breast cancer cells expressed high levels of NRP1,
while its expression was low in T-47D, BT-474, SK-BR-3, and
MDA-MB-453 cells (Figure 1A). Thus, breast cancer cells
express VEGF receptors in a differential manner, similar to
the observations of VEGF receptor expression in breast
tumor tissues [20]. Since MDA-MB-231 and MCF-7 cells
express VEGFR1, VEGFR2, and NRP1 (Figure 1), and since
MDA-MB-231 cells form tumors and metastasis in vivo in
nude mice, while MCF-7 cells form tumors in nude mice but
do not metastasize in vivo, both MDA-MB-231 and MCF-7 cell
lines were chosen for further analysis, as described below.
Down-Regulation of VEGF Expression Induces Apoptosis
in MDA-MB-231 Cells
To examine the role of endogenous VEGF in breast cancer
cells, we have generated MDA-MB-231 clones stably trans-
fected with antisense VEGF cDNA constructs. As shown in
Figure 1C, VEGF expression in these clones (AS-C1 and AS-
C2) was dramatically down-regulated (about 70%, as deter-
mined by densitometry) compared to the control cells. The
effects of VEGF antisense on apoptosis were also examined by
cell cycle analysis and TUNEL assays. As shown in Figure 1D,
cell cycle analysis revealed a higher percentage of apoptotic
cells in the AS-C1 (11.28% 6 2.7%) and AS-C2 (14.47% 6
2.8%) clones, as compared to the parental (0.74% 6 0.05%)
and pZeoSV control cells (0.51% 6 0.12%) (the results
represent the mean 6 standard deviation [SD] of three
independent experiments). Similar apoptotic effects were
observed in AS-C1 and AS-C2 cells using the TUNEL assay.
Higher percentages of cells with apoptotic morphology were
observed and quantitated in the AS-C1 (17.5% 6 0.7%) and
AS-C2 (22.5% 6 2.12%) as compared to parental (2.5% 6
0.7%) and pZeoSV control (5.0% 6 2.8%) cells (these data
reﬂect the mean 6 SD of three independent experiments)
(Figure 1E). To further conﬁrm these results, MDA-MB-231
cells were transiently transfected with siRNA oligonucleotides
for VEGF or with siCTL for 5 d. As shown in Figure 1F,
siVEGF induced a knock-down in VEGF production and
reduced the survival of the MDA-MB-231 cells as compared to
the siCTL. Cells transfected with siCTL showed a low rate of
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apoptosis was observed in cells transfected with siVEGF
(15.89% 6 1.91%). Thus, endogenous VEGF mediated the
survival of MDA-MB-231 cells.
Autophosphorylation of VEGFR2 in MDA-MB-231 Cells
Next, we studied whether VEGF can induce the phosphor-
ylation of VEGFR2 in MDA-MB-231 cells, similar to its effects
in endothelial cells. HBMECs and MDA-MB-231 cells were
treated with VEGF (30 ng/ml). Total cell lysates were prepared
and immunoprecipitated with anti-VEGFR2 antibody and
probed with 4G10 or anti-VEGFR2 antibodies. As shown in
Figure 2A, the VEGFR2 receptor was phosphorylated in
HBMECs upon VEGF stimulation, whereas the receptor was
constitutively phosphorylated in MDA-MB-231 cells irrespec-
tive of VEGF stimulation. These data suggest that endogenous
VEGF may be enough to induce activation of VEGFR2 in
these tumor cells. Because VEGF induces signal transduction
in endothelial cells via the formation of homo- and
heterodimers of the VEGF receptors VEGFR1 and VEGFR2
[21], we therefore examined which complex of the two
receptors is dominant in breast cancer cells. As shown in
Figure 2B, we observed that VEGFR2 did not interact with
VEGFR1, implying that endogenous VEGF may induce only
the homodimer form of VEGFR2.
Effect of VEGF on the Expression of VEGF Receptors
Based on the above experiments, we hypothesized that the
decrease in VEGFR2 phosphorylation induced by the lower
VEGF expression levels could cause the increased apoptosis
of AS-C1 and AS-C2 clones. To test this possibility, AS-C1 and
AS-C2 cell lysates (2 mg) were immunoprecipitated with
VEGFR2 polyclonal antibodies, as indicated. Unexpectedly,
we found that VEGFR2 protein expression was substantially
decreased in the AS-C1 and AS-C2 cells as compared to that
in the parental or pZeoSV cells (Figure 2C). We further
conﬁrmed these results using RT-PCR analysis (Figure 2D).
The expression of VEGFR1 and NRP1 was not altered in the
AS-C1 and AS-C2 cells (Figure 2C and 2D).
Neither VEGFR2 nor NRP1 Mediates the Survival of MDA-
MB-231 Cells
To directly examine the effects of reducing VEGFR2
expression on the survival of MDA-MB-231 cells, we speciﬁ-
cally lowered VEGFR2 expression using siVEGFR2 oligonu-
cleotides. First, we used oligonucleotides for four different
target sequences and examined the effects of each siRNA on
VEGFR2 mRNA transcription in the MDA-MB-231 cells using
RT-PCR (unpublished data). Following these experiments, we
selected a speciﬁc target sequence yielding high reduction in
VEGFR2 mRNA transcription (Figure 3A). We then con-
structed a retroviral vector encoding this sequence with which
to infect the MDA-MB-231 cells. As shown in Figure 3B and 3C,
these wild-type cells exhibited reduced VEGFR2 expression as
compared to the luciferase- or mutated VEGFR2-siRNA-
expressing cells, but no changes in VEGFR1 or NRP1
expression. However, no signiﬁcant cell death was observed
in the MDA-MB-231 cells expressing low levels of VEGFR2, as
compared to the control or parental cells (unpublished data).
Next, we examined the effect of NRP1 on the survival of
MDA-MB-231 cells, since VEGF was reported to mediate the
autocrine survival of these cells through NRP1 [14]. MDA-MB-
231 cells were preincubated with NRP1-targeted siRNA
(siNRP1) oligonucleotides (200 nM) or with siCTL for 5 d. As
shown in Figure 3D, while siNRP1 resulted in a complete
reductioninNRP1expressioninthe MDA-MB-231cells,nocell
death was observed in the siNRP1-treated cells (1.16% 6
0.25%) as compared to the siCTL-treated cells (0.29% 6 0.1%).
VEGFR1 Mediates the Survival of MDA-MB-231 Cells
Since we noticed high expression of VEGFR1 in various
breast cancer cell lines, we hypothesized that VEGFR1 may
mediate VEGF-induced survival in breast cancer cells. To
examine this possibility, we used oligonucleotides for four
different target sequences of VEGFR1 mRNA and examined
the effects of each siRNA on VEGFR1 protein expression in
the MDA-MB-231 cells upon Western blot analysis. We could
clearly detect a VEGFR1 protein band corresponding to 200
kDa upon Western blotting with 0.1 mg of total cell lysates
(Figure 4A). From these experiments, we found that one siRNA
oligonucleotide (#4) among the four different siVEGFR1
oligonucleotides induced signiﬁcant knockdown of VEGFR1
protein expression (Figure 4A). We also performed cell cycle
analysis to determine the effects of siVEGFR1 on apoptosis.
When MDA-MB-231 cells were treated with luciferase-targeted
siRNA (siLuc), siVEGFR1#1, siVEGFR1#2, siVEGFR1#3 and
siVEGFR1#4, the apoptosis rates were 3% (2.97% 6 0.26%),
1% (1.0% 6 0.15%), 2% (2.07% 6 0.16%), 5% (4.82% 6
0.42%), and 17% (17.04% 6 0.53%), respectively (Figure 4A).
These data show that cells treated with siVEGFR1#4 resulted in
a dramatic reduction in VEGFR1 expression and in a higher
rate of apoptosis. To eliminate the nonspeciﬁc effect of
functional siVEGFR1 on MDA-MB-231 cell survival, we used
mutated siVEGFR1 oligonucleotides. The MDA-MB-231 cells
were preincubated with wild-type or mutated siVEGFR1
oligonucleotides (200 nM) for 5 d. As shown in Figure 4B,
the wild-type siVEGFR1-treated cells exhibited a reduction in
VEGFR1 mRNA transcription, as compared to the luciferase or
mutant siVEGFR1-treated cells. Furthermore, these effects
were speciﬁc for VEGFR1, since no changes were observed in
VEGFR2 expression under these conditions (Figure 4B). Using
cell cycle analysis, the apoptosis rates were 38.1% (38.14% 6
2.06%) in the MDA-MB-231 cells treated with wild-type
siVEGFR1, as compared to cells treated with either luciferase
(4.87% 6 0.45%) or mutant siVEGFR1 (6.28% 6 0.62%)
(Figure 4B).
Next, we investigated the effects of siVEGFR1#4 on tumor
formation in vivo in nude mice. MDA-MB-231 cells were
treated with 200 nM of siVEGFR1#4 or siCTL for 2 d.
Aliquots of these cells were then analyzed by Western blotting
to verify the signiﬁcant knockdown (.90%) of VEGFR1 in the
siVEGFR1-treated cells. Cells were next harvested and
inoculated into nude mice, and tumor formation was
monitored in these mice. As shown in Figure 4C, the tumors
in mice treated with siVEGFR1 were signiﬁcantly smaller than
those in mice treated with siCTL or in the untreated group.
Thus, these in vitro and in vivo results demonstrate that
VEGFR1 mediated the survival of the MDA-MB-231 cells.
VEGFR1 Mediates AKT Phosphorylation in MDA-MB-231
Cells
It has been reported that VEGFR1 mediates the survival of
endothelial cells through the phosphatidylinositol 3-kinase/
AKT pathway [2]. Thus, to test whether VEGFR1 can also
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Survival of VEGF through VGFR1Figure 1. Expression of VEGF Receptors in Breast Cancer Cells and Apoptosis of MDA-MB-231 Cells by Down-Regulation of VEGF
(A) VEGF receptor expression was examined by using immunoprecipitation (IP) and Western blot (WB) analyses in several breast cancer cell lines.
(B) VEGFR2 expression in MDA-MB-231 cells was analyzed by confocal microscopy. Cells were stained with anti-VEGFR2 antibody or IgG (inset). The
asterisk indicates cells transduced with adenovirus encoding soluble human VEGFR2, which served as a positive control.
(C) MDA-MB-231 cells were transfected with antisense VEGF vector and selected in the presence of Zeocin (1 mg/ml). VEGF expression in the MDA-MB-
231 transfectants (pZeoSV, AS-C1, and AS-C2) was assessed by Western blotting (WB) using a polyclonal anti-VEGF antibody. Total protein extracts were
analyzed by Western blotting using anti-Csk antibody as an internal control.
(D and E) MDA-MB-231 cells were stably transfected with antisense VEGF vector and the survival of these cells was measured by using cell cycle analysis
(D) and TUNEL assay (E).
(F) MDA-MB-231 cells were transiently transfected with siCTL or siVEGF oligonucleotides, and VEGF was quantitated in the supernatants (left graph)
using an ELISA kit as directed by the manufacturer. The apoptosis of these cells was measured by using cell cycle analysis. The data are representative of
three individual studies (right graphs).
doi:10.1371/journal.pmed.0040186.g001
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Survival of VEGF through VGFR1mediate breast cancer cell survival through this pathway,
MDA-MB-231 cells were treated with siVEGFR1 oligonucleo-
tides, and AKT phosphorylation was examined in these cells.
As shown in Figure 4D, wild-type siVEGFR1 reduced AKT
phosphorylation in MDA-MB-231 cells, whereas the lucifer-
ase-expressing cells or cells transfected with mutant si-
VEGFR1 had no effect. These data suggest that VEGFR1
might mediate the survival of MDA-MB-231 cells through
AKT phosphorylation.
The VEGF/VEGFR1 Axis Mediates the Survival of MCF-7
Breast Cancer Cells
We next examined the effects of the VEGF/VEGFR1 axis on
another breast cancer cell system, MCF-7 cells, in addition to
MDA-MB-231 cells. As expected, the reduction in VEGF or
VEGFR1 expression induced signiﬁcant cell death in the
MCF-7 cells, whereas the reduction in NRP1 or VEGFR2
expression had no signiﬁcant effects on the survival of these
cells (Figure 5A–5C). MCF-7 cells treated with siLuc,
siVEGFR2, siNRP1, and mutant siVEGFR1 showed apoptosis
rates of 0.7% (0.71% 6 0.09%), 0.70% (0.69% 6 0.19%),
1.50% (1.53% 6 0.30%) and 4.1% (4.2% 6 0.39%),
respectively, while cells treated with either siVEGF (16.5%
6 0.69%), siVEGF with VEGF (14.54% 6 0.57%), siVEGF
with PGF (13.95% 6 0.07%), or wild-type siVEGFR1 (16.70%
6 0.29%) showed a substantial increase in apoptosis. Thus,
these data suggest that VEGF might mediate survival in a
broad range of breast cancer cells via VEGFR1.
Neither Exogenous VEGF nor Exogenous PGF Inhibits
Apoptosis Following Reduced VEGF Expression in Breast
Cancer Cells
To further investigate whether VEGFR1 can play a role in
the VEGF-mediated autocrine survival of MDA-MB-231 or
MCF-7 cells, these cells were transiently transfected with
siVEGF oligonucleotides in the presence of exogenous VEGF
or the VEGFR1-speciﬁc ligand PGF (20 ng/ml). siVEGF
resulted in a signiﬁcant decrease in the survival of both
MCF-7 and MDA-MB-231 cells (Figure 5B and 5D). Cell cycle
analysis showed that the apoptosis rate of MDA-MB-231 cells
treated with siVEGF was 15% (15.1% 6 0.23), which was
about 15-fold higher than cells treated with siLuc (1.0% 6
0.26%) (Figure 5D). Furthermore, exogenous addition of
VEGF or PGF to both MCF-7 and MDA-MB-231 cells did not
abrogate the effects of siVEGF on the apoptosis of these cells
(Figure 5B and 5D). Since PGF failed to rescue the survival of
siVEGF-treated cells, this prompted us to study the local-
ization of VEGFR1 expression in MDA-MB-231 and MCF-7
breast cancer cells. As shown in Figure 6, no VEGFR1
expression was detected at the surface of the MDA-MB-231
cells, while expression of VEGFR1 in the MCF-7 cells was low.
The VEGFR1 antibodies used in these studies were speciﬁc
for the detection of the full-length membrane form of
VEGFR1. However, when these cells were permeabilized, we
observed positive expression of VEGFR1 in both cell lines,
indicating that VEGFR1 is expressed internally in both MDA-
MB-231 and MCF-7 cells. We next examined the expression of
VEGFR1 in the cytoplasmic and nuclear fractions of MDA-
MB-231 cells as compared to HUVECs. Cellular fractions were
subjected to Western blot analysis for VEGFR1, lamin B1 (a
nuclear marker), GAPDH (a cytoplasmic marker), and actin.
The levels of VEGFR1 expression in the cytoplasmic and
Figure 2. VEGF Receptor Expression in VEGF-Reduced MDA-MB-231 Cells
(A) MDA-MB-231 cells and HBMECs were treated with VEGF (30 ng/ml) to
examine its effects on the phosphorylation (top blots) and expression
(bottom blots) of VEGFR2. Total cell lysates were prepared and then
subjected to immunoprecipitation (IP) and Western blotting (WB) using
4G10 or anti-VEGFR2 antibodies. The arrowhead indicates a nonspecific
protein band.
(B) Lysates (5 mg) from MDA-MB-231 cells were immunoprecipitated by
using anti-VEGFR1 or anti-VEGFR2 antibodies. The immune complexes
were analyzed by Western blotting using anti-VEGFR2 antibodies. After
stripping, the membrane was subjected to Western blotting using anti-
VEGFR1 antibodies.
(C) Lysates (2 mg) from variously transfected MDA-MB-231 cells were
subjected to immunoprecipitation (IP) and Western blot (WB) analyses
for VEGF and NRP1 receptor expression, as indicated. Total protein
lysates (0.4 mg) from HBMECs were used as a positive control.
(D) Total RNA (5 lg) from variously transfected MDA-MB-231 cells was
subjected to RT-PCR analysis for VEGFR1 or VEGFR2 mRNA expression.
GAPDH mRNA is shown as an internal control.
doi:10.1371/journal.pmed.0040186.g002
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Survival of VEGF through VGFR1nuclear fractions were quantitated by Scion image software.
The data were normalized to the actin levels, and were
expressed as relative units of VEGFR1 expression. The
expression levels of VEGFR1 differed between the MDA-MB-
231 cells and HUVECs (Figure 6B): a signiﬁcantly higher level
of VEGFR1 was detected in the nuclear fraction in MDA-MB-
231 cells than in HUVECs. These results support the
observation that VEGFR1 is mostly expressed internally in
breast cancer cells.
To further determine the sublocalization of VEGFR1 in
MCF-7 and MDA-MB-231 cells, we performed confocal
analysis of these cells following their immunostaining with
antibodies against the intermediate ﬁlament protein LMNA
(which is expressed speciﬁcally at the nuclear envelope) and
with VEGFR1 antibodies (which are speciﬁc to the extrac-
ellular domain of VEGFR1). As shown in Figure 7, VEGFR1
was mainly observed in the nuclear envelope of these cells. In
addition, VEGFR1 was colocalized with LMNA at the nuclear
envelope of both the MCF-7 and MDA-MB-231 cells. Merging
of the VEGFR1 and LMNA immunostaining conﬁrmed the
colocalization of VEGFR1 with LMNA at the nuclear
envelope in these cells. We further conﬁrmed these results
with additional antibodies against VEGFR1 that speciﬁcally
recognize the membrane form of VEGFR1 and do not cross-
react with soluble VEGFR1 (unpublished data). To demon-
strate the speciﬁcity of the staining, we treated MDA-MB-231
cells with siCTL or with wild-type or mutant siVEGFR1, and
analyzed the cells for the expression and sublocalization of
VEGFR1. As shown in Figure 8, the siVEGFR1 treatments
resulted in a substantial decrease in VEGFR1 expression in
these cells. Speciﬁcally, no expression of VEGFR1 was
observed in the nuclear envelope nor was any colocalization
of VEGFR1 with LMNA found in these cells, as compared to
the control siRNA-treated cells.
We next examined the expression of VEGFR1 in ten
sporadic breast cancer tumors. As shown in Figure 9, strong
expression of VEGFR1 was found in the nuclear envelope and
the cytoplasm of these tissues (Figure 9A and 9B), whereas
VEGFR1 expression was mainly observed at the nuclear
envelope in normal mammary gland tissues (Figure 9C and
9D). No membrane staining of VEGFR1 was observed in
breast tumor or normal mammary gland tissues. Therefore,
although VEGFR1 is expressed as a plasma membrane protein
in endothelial cells, it is mainly expressed in the nuclear
envelope in breast cancer cell lines, primary breast tumors,
and normal mammary glands.
VEGF and Its Protein Inhibitors Have No Biological Effects
on Breast Cancer Cells
Based on the VEGFR1 localization results (Figure 6), we
tested whether functional blocking of VEGFR1 would inhibit
the growth or survival of breast cancer cells. For these
experiments, we used VEGFR1-speciﬁc blocking antibody,
which is known to inhibit the VEGF-induced migration of
monocytes expressing VEGFR1 only [17]. MDA-MB-231 and
MCF-7 cells were seeded onto six-well plates at a density of
5,000 cells per well. Following 4 d of treatment with the
speciﬁc blocking antibody, cell proliferation was analyzed.
The proliferation rates were similar in the MDA-MB-231 cells
treated with 0, 2, and 10 lg/ml of VEGFR1 blocking antibody
100% (100% 6 9.16%), 88% (87.66% 6 8.08%), and 91%
(91.11% 6 7.56%), respectively (Figure 10). Similar observa-
tions were made in MCF-7 cells treated with 0, 2, and 10 lg/ml
of the VEGFR1 blocking antibody: the proliferation rates
were 100% (100.12% 6 9.53%), 87% (86.66% 6 17.67%) and
100% (100.33% 6 12.70%) in the cells, respectively (Figure
Figure 3. Effects of siVEGFR2 or siNRP1 Oligonucleotides on the Survival
of MDA-MB-231 Cells
(A) The siRNA oligonucleotides (and their sequences) used in this study
were purchased from Dharmacon.
(B) MDA-MB-231 cells were infected with retrovirus encoding wild-type
(w) or mutant (m) siVEGFR2 or siLuc and then selected with puromycin (5
lg/ml). Total RNA (5 lg) was subjected to RT-PCR analysis for VEGFR2
mRNA expression. GAPDH mRNA is shown as an internal control.
(C) Total protein extracts (5 mg) from puromycin-selected cells were
subjected to immunoprecipitation (IP) and Western blot (WB) analyses
for VEGF and NRP1 receptor expression, as indicated.
(D) MDA-MB-231 cells were transiently transfected with siCTL or siNRP1
oligonucleotides. After 5 d of incubation, total cell lysates were prepared
and subjected to Western blotting (WB) using anti-NRP1 antibodies (left
blots). Total protein extracts were analyzed by Western blotting using
anti-Csk antibody as an internal control. The survival of siNRP1-treated
cells was measured by using cell cycle analysis. The data are
representative of three individual studies (right graphs).
doi:10.1371/journal.pmed.0040186.g003
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Survival of VEGF through VGFR110). Thus, this antibody did not inhibit the proliferation of
the MDA-MB-231 and MCF-7 cells. Using cell cycle analysis,
we conﬁrmed that this antibody had no effect on the survival
of these cancer cells, since VEGFR1 is mostly expressed
internally and not on the surface of breast cancer cells as
expected (unpublished data). These results are consistent with
our previous report showing that VEGF had no effect on the
invasion of MDA-MB-231 cells [19]. In addition, VEGF
blocking antibody or soluble VEGFR1 protein had no effect
on the survival or proliferation of MDA-MB-231 cells
(unpublished data). Taken together, these data indicate that
VEGF plays a role as an intracrine survival factor in breast
carcinoma cells through VEGFR1, which is mainly expressed
internally.
Discussion
In this study, we found that several breast cancer cell lines
expressed VEGF receptors. Furthermore, we showed that
reduced endogenous VEGF or VEGFR1 expression induced
the apoptosis of MDA-MB-231 and MCF-7 breast cancer cells,
whereas externally acting proteins (VEGF, VEGF antibody,
soluble VEGFR1, and VEGFR1-blocking antibody) had no
signiﬁcant effects on breast cancer cell growth or survival. We
also observed that internally expressed VEGFR1 induced the
survival of breast cancer cells. These results indicate that
VEGF plays a role as an internal autocrine survival factor in
breast cancer cells via VEGFR1 and not through VEGFR2 or
NRP1, and suggest that the role of the VEGF/VEGFR1 axis in
breast cancer cells may not be governed by the classical
paradigm of signal transduction involving interaction be-
tween ligands and cell surface receptors.
VEGF contributes to the growth of solid tumors, such as
breast cancer, through angiogenesis rather than through a
direct contribution to tumor cell survival. This effect seems to
be derived partly from the poor response of tumor cells to
externally acting molecules such as VEGF or antibodies to
VEGF. However, this concept has now been challenged by
recent reports showing that some cancer cells express VEGF
receptors on their surfaces in vitro and in vivo, and that in
several tumor cell types, including leukemia and melanoma
cells, VEGF acts as an autocrine survival factor [22,23].
Figure 4. Effects of VEGFR1 siRNA Oligonucleotides on the Survival of
MDA-MB-231 Cells
(A) Effects of siVEGFR1 oligonucleotides on the apoptosis of MDA-MB-
231 cells. MDA-MB-231 cells were transiently transfected with siLuc or
with various siVEGFR1 oligonucleotides (#1 through #4). After 5 d of
incubation, the cells were lysed and subjected to Western blotting (WB)
using anti-VEGFR1 antibodies. Total protein extracts were analyzed by
Western blotting using anti-Csk antibody as an internal control. The
apoptosis of siVEGFR1-treated cells was analyzed by using cell cycle
analysis, as indicated.
(B) MDA-MB-231 cells were transiently transfected with wild-type (w) or
mutated (m) siVEGFR1 oligonucleotides for 5 d. Total RNA (5 lg) was
subjected to RT-PCR analysis for VEGFR1 and VEGFR2 mRNA expression;
GAPDH mRNA is shown as an internal control (top gels). The survival of
siVEGFR1-treated cells was measured by using cell cycle analysis (lower
graphs). The data are representative of four individual studies.
(C) MDA-MB-231 cells (5310
6), transfected with either siVEGFR1 or siCTL,
were subcutaneously injected into the flank of athymic nude mice.
Tumors were measured at days 0, 5, and 10 (D-0, D-5, D10, respectively)
and expressed in cm
3. Number of mice per group is indicated by n-value.
*p , 0.05.
(D) MDA-MB-231 cells were transiently transfected with siLuc or with
wild-type (w) or mutated (m) siVEGFR1 oligonucleotides. After 5 d of
incubation, total cell lysates were prepared and subjected to Western
blotting (WB) by using phospho-AKT (p-AKT) or VEGFR1 antibodies. Total
protein extracts were analyzed by Western blotting using anti-Csk
antibody as an internal control for loading.
doi:10.1371/journal.pmed.0040186.g004
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Survival of VEGF through VGFR1Figure 5. Effect of VEGF and VEGF Receptor siRNA Oligonucleotides on the Survival of MCF-7 Cells
(A) MCF-7 cells were transiently transfected with various VEGF or VEGF receptor siRNA oligonucleotides, as indicated. Transfection procedures were
performed with DharmaFECT-1 reagent according to the manufacturer’s protocol. After 5 d of incubation, the cells were lysed and subjected to Western
blotting (WB) using anti-VEGFR1 or anti-NRP1 antibodies. Total protein extracts were analyzed by Western blotting using anti-Csk antibody as an
internal control. Alternatively, after 5 d of transfection, total RNA (5 lg) was isolated and subjected to RT-PCR analysis for VEGF and VEGFR2 mRNA
expression. GAPDH mRNA is shown as an internal control.
(B) MCF-7 cells were transiently transfected with siLuc, siNRP1, siVEGF, or various VEGF receptor siRNA oligonucleotides in the absence or presence of
PGF (20 ng/ml) or VEGF (20 ng/ml), as indicated. After 5 d of incubation, the cells were harvested and subjected to cell cycle analysis. The data are
representative of three individual studies. m, mutant; w, wild type.
(C) MCF-7 cells were transiently transfected with siLuc, siNRP1, siVEGF, or various VEGF receptor siRNA oligonucleotides as shown. After 5 d of
incubation, the cells were observed under a light microscope.
(D) Effect of VEGF on the cell cycle in MDA-MB-231 cells. MDA-MB-231 cells were transiently transfected with siLuc or with siVEGF oligonucleotides in
the presence or absence of VEGF (20 ng/ml). After 5 d of incubation, cells were harvested and subjected to cell cycle analysis. The data are
representative of three individual studies.
doi:10.1371/journal.pmed.0040186.g005
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Survival of VEGF through VGFR1Although breast cancer cell lines express both VEGF and the
VEGF receptors VEGFR1, VEGFR2, and NRP1 [11], the
expression of these receptors in primary breast tumors is
controversial [12,13,24–28]. Dales et al [12] reported that
VEGFR1 and VEGFR2 were strongly expressed in endothelial
cells within blood microvessels, and weakly expressed in
tumor cells in a series of 918 patients. Univariate analysis
showed that the expression of VEGFR1 in tumor cells was not
correlated with survival, but was signiﬁcantly correlated with
high metastasis risk [12]. In another study involving 905 cases
of breast cancer tumors [29], the expression of VEGFR1 was
correlated with a high risk of local recurrence. On the other
hand, VEGFR1 expression was rarely observed in 205 cases of
ductal carcinoma in situ of the breast [13]. Thus, there are
conﬂicting reports regarding the expression and role of
VEGFR1 in breast cancer. No correlation between survival
and metastasis risk and relapse was found in breast cancer
cells that expressed VEGFR2 [12]. Therefore, the role of
VEGF as an angiogenic factor and/or as a survival factor in
tumor cells needs to be fully investigated.
Figure 6. Internal Expression of VEGFR1 in Breast Cancer Cells
(A) VEGFR1 expression in MDA-MB-231 and MCF-7 cells was analyzed using flow cytometry, under permeable and nonpermeable conditions. VEGFR1
expression (grey tracing) is detected mostly internally under permeable conditions. Staining with control antibody is indicated by the black tracing.
(B) Cytoplasmic and nuclear fractions extracted from MDA-MB-231 cells and HUVEC were subjected to Western blotting (WB) using anti-VEGFR1, anti-
lamin B1, anti-GAPDH, and anti-actin antibodies. The figure shows the relative expression levels of VEGFR1 in the cytoplasmic (CE) and nuclear (NE)
extracts from MDA-MB-231 cells and HUVEC. *p , 0.05.
doi:10.1371/journal.pmed.0040186.g006
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Survival of VEGF through VGFR1Our siRNA studies on VEGF receptors revealed that VEGF
can modulate the survival of breast cancer cells via VEGFR1,
but not VEGFR2. Here, we show that VEGFR1 mediated AKT
phosphorylation, a major survival pathway in breast cancer
cells. It is known that VEGF mediates most angiogenic
processes by interacting with VEGFR2 in endothelial cells.
VEGF can also modulate VEGFR2 expression as well as its
phosphorylation in endothelial cells [30]. Thus, down-regu-
lation of VEGF expression may induce apoptosis in the MDA-
MB-231 clones AS-C1 and AS-C2 through the decreased
VEGFR2 expression in these cells. However, our studies with
siVEGFR2 demonstrated that VEGFR2 is not important for the
survival of breast cancer cells. Although VEGFR2 has strong
tyrosine kinase activity compared to VEGFR1 in endothelial
Figure 8. Localization of VEGFR1 in MDA-MB-231 Cells after siVEGFR1 Treatment
MDA-MB-231 cells were transfected with siCTL, mutant siVEGFR1 (siVEGFR1m), or wild-type siVEGFR1 (siVEGFR1w), and then stained with anti-VEGFR1
and anti-LMNA (Lamin A/C) antibodies. Strong nuclear envelope staining and weak nuclear and cytoplasmic staining were observed for the VEGFR1
protein in the control siCTL and siVEGFR1m-transfected cells, whereas VEGFR1 protein expression was significantly decreased in the siVEGFR1w-
transfected cells, and no VEGFR1 expression was observed in the nuclear envelope. The merged staining indicates the colocalization of VEGFR1 and
LMNA.
doi:10.1371/journal.pmed.0040186.g008
Figure 7. Localization of VEGFR1 in MCF-7 and MDA-MB-231 Cells
Cells were stained with anti-VEGFR1 and anti-LMNA (Lamin A/C; a nuclear envelope marker) antibodies. Localization of VEGFR1 was then examined
using confocal microscopy. LMNA was specifically localized at the nuclear envelope. Strong VEGFR1 protein expression was observed in the nuclear
envelopes of the MCF-7 and MDA-MB-231 cells. Merged staining shows colocalization of VEGFR1 and LMNA at the nuclear envelopes.
doi:10.1371/journal.pmed.0040186.g007
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Survival of VEGF through VGFR1cells, the level of VEGFR2 expression in MDA-MB-231 and
MCF-7 breast cancer cells might not be sufﬁcient to induce
VEGF-mediated signaling in these cells. In fact, we almost
could not detect VEGFR2 protein expression by immunopre-
cipitation, nor could we detect any expression of this protein
by immunocytochemical analysis (Figure 1A and 1B).
VEGFR2 tyrosine phosphorylation was reported to be
enhanced by VEGF in breast cancer and to lead to increased
ERK1/2 (extracellular signal-regulated kinase 1/2) and AKT
phosphorylation, suggesting that VEGF stimulation is impor-
tant in the regulation of cell growth, apoptosis, and differ-
entiation [31]. VEGFR2 was also shown to be expressed on the
surface of breast cancer cells [31]. However, these results
differ from our data since the level of expression of VEGFR2
was very low in our cell system, and knockdown of VEGFR2 by
siRNA treatment had no effect on the apoptosis of breast
cancer cells. Additionally, we examined the effect of NRP1 on
the survival of MDA-MB-231 cells, as it was previously
reported that VEGF mediates the autocrine survival of these
cells through NRP1 [14]; we failed to show that NRP1
mediated VEGF-induced survival in MDA-MB-231 cells.
NRP1 is known to interact with VEGFR1 but has a very short
cytoplasmic domain [32], suggesting that NRP1 may not
directly transduce VEGF-mediated signaling in these cells.
Although we can not fully explain these discrepancies, based
on our results it is unlikely that VEGFR2 or NRP1 has a direct
functional effect on VEGF-mediated survival in MDA-MB-231
cells. Knockdown of endogenous VEGF expression or
addition of VEGFR synthetic inhibitors resulted in the
apoptosis of hematopoietic stem cells [33], whereas VEGF
or soluble VEGFR1 did not have any effect on the survival of
these cells. Therefore, the survival mechanism of VEGF in
breast cancer cells might be different from that of VEGF in
endothelial cells, and may mimic the VEGF-dependent
survival system in hematopoietic stem cells [33].
VEGFR1 was originally thought to be a receptor speciﬁ-
cally expressed in vascular endothelial cells. However, some
studies have shown that VEGFR1 is expressed in tumor cells
and is involved in tumor growth and progression [5,6,20,34].
VEGF has also been shown to increase the invasiveness of
colorectal cancer cells or myeloma cells [15,16], and VEGFR1-
blocking antibody was reported to inhibit the VEGF-induced
Figure 9. Localization of VEGFR1 Protein in Human Breast Tissues
Tissue sections from human breast tumors and normal mammary glands were stained with anti-VEGFR1 and anti-LMNA (Lamin A/C) antibodies to
determine their localization.
(A and B) VEGFR1 was intensively colocalized with the nuclear envelope marker LMNA at the nuclear envelope and in the cytoplasm in human breast
tumors.
(C and D) VEGFR1 was colocalized with LMNA at the nuclear envelope in normal mammary glands.
doi:10.1371/journal.pmed.0040186.g009
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Survival of VEGF through VGFR1invasiveness of these cells [15,16]. These results indicate that
VEGF can act as an autocrine or paracrine factor in the
invasiveness of both cell types via VEGFR1. These previously
published studies are different from our present data, which
show that neither exogenous VEGF nor VEGFR1-blocking
antibody has any signiﬁcant effects on the invasiveness or
survival of breast cancer cells. We observed that VEGFR1 was
expressed internally, but not on the surface of breast cancer
cells. The localization of VEGFR1 expression in breast cancer
cells is a novel ﬁnding that may support our observations that
VEGF plays a role as an internal autocrine survival factor in
these cells. It remains to be elucidated how VEGFR1 is
expressed internally in breast cancer cells, and how it
mediates VEGF-induced survival in these cells.
The results of our studies differ from those of studies by
Vincent et al. [16] showing that VEGF facilitated the growth
and survival of human primary multiple myeloma cells via
VEGFR1. In that study, VEGFR1 was shown to be present in the
cytoplasm and the nuclei of proliferating multiple myeloma
cells. Vincent et al. [16] reported that a monoclonal antibody
against VEGFR1 inhibited the proliferation and migration of
primary multiple myeloma cells via plasma membrane reten-
tion of VEGFR1 following the prevention of its nuclear
translocation. In our study, however, externally acting growth
factors, such as VEGF and VEGFR1-blocking antibody, had no
effects on breast cancer cell growth or survival. Furthermore,
VEGFR1 receptors were mostly expressed internally, and not
on the surface of breast cancer cells, which may provide a
mechanism for the lack of inhibition of breast cancer cell
growth by antibody to VEGFR1. We also observed localization
of VEGFR1 mainly in the nuclear envelope in breast cancer cell
lines, primary breast cancer tumors, and normal mammary
glands. These results suggest that the expression pattern,
localization, and function of VEGFR1 may differ between
breast epithelial cells and endothelial cells.
Although VEGF has a signal peptide that induces its direct
secretion through the classical secretory pathway, VEGF can
also translocate to the nucleus [35]. Moreover, VEGF contains
basic amino acids that could act as potential nuclear local-
ization signals [36]. Recent studies showed that VEGF protein
colocalizes with the RNA-binding protein HuR in discrete
nuclear compartments and that nuclear VEGF protein is
increasedinhypoxia[36].Theseresults indicate thatVEGFmay
have a nuclear function, especially during hypoxia. Further-
more, VEGF nuclear accumulation is correlated with pheno-
typic changes in endothelial cells [30]. VEGF is internalized via
the classical receptor-mediated endocytosis pathway and
accumulates in the endosomal compartment, whereas in cells
situated at the edges of a wound, VEGF is rapidly taken up and
translocated to the nucleus [30]. Therefore, it is possible that
VEGF may be retained within the cell for its interaction with
perinuclear VEGFR1. Future studies will address the function
of VEGFR1 in live breast cancer cells and normal breast
epithelial cells, and determine the kinetics, translocation, and
binding of VEGFR1 to VEGF in these cells.
The limitation of our study is that the intracrine role of
VEGF/VEGFR1 was examined in two breast cancer cell lines
and in only a few samples of primary breast tumors. These
results may not be fully applicable to all breast cancer
samples, representing different stages of the disease. Thus,
further studies of breast cancer cells from patients at
different clinical stages of the disease will be necessary to
deﬁne the pathophysiologic role of the VEGF/VEGFR1 axis in
intracrine signaling. In addition, although we were able to
examine the functional blocking of VEGFR1 using antibodies
that were readily accessible to our laboratory, other VEGFR1
antibodies (that are currently unavailable to us) need to be
examined for their effects on breast cancer cell growth and
proliferation in vivo in this system, once these antibodies
become available.
Recently it was reported that VEGFR1 expression was
signiﬁcantly increased in breast cancer patients with a poor
prognosis [37]. Consistent with that report, our data suggest
that VEGFR1 might be an attractive target for therapeutic
approaches in patients with malignant breast cancer. Fur-
thermore, our data suggest that intracellularly acting inhib-
itors against VEGF and its receptor VEGFR1 might be a more
effective therapeutic method for breast cancer patients as
compared to the externally acting inhibitors. Speciﬁcally, the
former approach will exert direct tumor-killing effects as well
as antiangiogenic effects, while the latter approach will exert
indirect tumor-killing effects through antiangiogenic activity
alone. Hence, our study may provide an optimal strategy for
tumor therapy based on the inhibition of angiogenesis.
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Figure 10. Effects of VEGFR1 Antibody on Cell Growth
MDA-MB-231 and MCF-7 cells were grown subconfluently on six-well
plates and treated with various concentrations of monoclonal antibody
to VEGFR1. After 4 d of incubation, cells were harvested and counted on
a hemocytometer. Data are presented as the means 6 SD of three
individual studies.
doi:10.1371/journal.pmed.0040186.g010
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Survival of VEGF through VGFR1Editors’ Summary
Background. One woman in eight will develop breast cancer during her
lifetime. Most of these women live for many years after their diagnosis
and many are cured of their cancer. However, sometimes the cancer
grows inexorably and spreads (metastasizes) around the body despite
the efforts of oncologists. Characteristics of the tumor known as
prognostic factors can indicate whether this spreading is likely to
happen. Large tumors that have metastasized have a poorer prognosis
than small tumors that are confined to the breast. The expression of
specific proteins within the tumor also provides prognostic information.
One protein whose expression is associated with a poor prognosis is
vascular endothelial growth factor (VEGF). VEGF stimulates angio-
genesis—the growth of new blood vessels. Small tumors get the
nutrients needed for their growth from existing blood vessels but large
tumors need to organize their own blood supply. They do this, in part, by
secreting VEGF. This compound binds to proteins (receptors) on the
surface of endothelial cells (the cells lining blood vessels), which then
send a signal into the cell instructing it to make new blood vessels.
Angiogenesis inhibitors, including molecules that block the activity of
VEGF receptors, are being developed for the treatment of cancer.
Why Was This Study Done? Some breast cancer cell lines (cells isolated
from breast cancers and grown in the laboratory) make VEGF and VEGF
receptors (VEGFR1, VEGFR2, and neuropilin 1 [NRP1]). But, although
some studies have reported an association between VEGFR1 expression
in breast tumors and a poor prognosis, other studies have found no
expression of VEGFR1 in breast tumors. Consequently, the role of VEGF
receptors in breast cancer is unclear. In this study, the researchers
analyzed the expression and function of VEGF and its receptors in breast
cancer cells to investigate whether and how VEGF helps these cells to
survive.
What Did the Researchers Do and Find? The researchers first examined
the expression of VEGF receptors in several human breast cancer cell
lines. All of them expressed VEGFR1, some expressed NRP1, but VEGFR2
expression was universally low. They then investigated the function of
VEGF and its receptors in two human breast cancer cell lines (MDA-MB-
231 and MCF-7). In both cell lines, blocking the expression of VEGF or of
VEGFR1 (but not of the other two receptors) reduced cell survival by
stimulating a specific process of cell death called apoptosis. Unexpect-
edly, adding VEGF to the cultures did not reverse the effect of blocking
VEGF expression, a result that suggests that VEGF and VEGFR1 do not
affect breast cancer cell survival by acting at the cell surface. Accordingly,
when the researchers examined where VEGFR1 occurs in the cell, they
found it on the membranes around the nucleus of the breast cancer cell
lines and not on the cell surface; several primary breast tumors and
normal breast tissue had the same localization pattern. Finally, the
researchers showed that inhibitors of VEGF action that act at the cell
surface did not affect the survival of the breast cancer cell lines.
What Do These Findings Mean? These findings suggest that VEGF
helps breast cancer cells to survive in a unique way: by binding to
VEGFR1 inside the cell. In other words, whereas VEGF normally acts as a
paracrine growth factor (it is released by one cell and affects another
cell), in breast cancer cells it might act as an internal autocrine
(intracrine) survival factor, a factor that affects the cells in which it is
produced. These findings need confirming in more cell lines and in
primary breast cancers but could have important implications for the
treatment of breast cancer. Inhibitors of VEGF and VEGFR1 that act inside
the cell (small molecule drugs) might block breast cancer growth more
effectively than inhibitors that act at the cell surface (for example,
proteins that bind to the receptor), because internally acting inhibitors
might both kill the tumor directly and have antiangiogenic effects,
whereas externally acting inhibitors could only have the second effect.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040186.
  US National Cancer Institute information for patients and professionals
on breast cancer (in English and Spanish) and on angiogenesis (in
English and Spanish)
  MedlinePlus Encyclopedia information for patients on breast cancer (in
English and Spanish)
  CancerQuest, information from Emory University on cancer biology
and on angiogenesis and angiogenesis inhibitors (in several
languages)
  Wikipedia pages on VEGF (note: Wikipedia is a free online
encyclopedia that anyone can edit; available in several languages)
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